Clinical Trial Detail

NCT ID NCT03260504
Title Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Washington
Indications

clear cell renal cell carcinoma

renal cell carcinoma

Therapies

Aldesleukin + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.